A Surprising Side Effect Unveiled: The Unseen Impact of Ozempic and Wegovy
In a recent study that has sparked curiosity and concern, scientists have uncovered a new potential side effect linked to drugs like Ozempic and Wegovy. While these medications are known for their weight-loss benefits and diabetes management, the research suggests there's more to the story.
Many users have experienced digestive issues, such as nausea, vomiting, and changes in bowel movements, along with headaches and fatigue. But here's where it gets controversial: scientists are now warning of an additional side effect that could make you feel under the weather and impact your daily life.
The study, published on Wednesday, analyzed medical records of over 2 million patients across the country, spanning from 2005 to 2025. Researchers identified a significant number of patients, approximately 427,555, who had been prescribed GLP-1 medications for Type 2 diabetes. These drugs mimic the hormone glucagon-like peptide-1, which plays a crucial role in regulating insulin production, digestion, and appetite.
When comparing these patients to a control group of 1.6 million Type 2 diabetes patients on other common medications, the researchers found a startling difference. Patients taking GLP-1 medications had up to a 29% higher risk of developing a chronic cough within the first five years of treatment. A chronic cough is defined as one lasting eight weeks or longer, and it can significantly impact an individual's quality of life.
And this is the part most people miss: GLP-1 users were also more likely to be diagnosed with gastroesophageal reflux disease (GERD), which can trigger a dry cough. Even when participants with pre-existing GERD were excluded, the link between GLP-1 use and a chronic cough remained significant.
The study authors wrote, "This cohort study suggests an association between GLP-1 receptor agonist use and a new diagnosis of chronic cough." However, they emphasize the need for further research to confirm this link and understand the underlying biological mechanisms.
As scientists explore new applications for GLP-1s beyond weight loss and diabetes management, the findings raise important questions. Last year, the US FDA approved Wegovy to reduce cardiovascular risk in overweight adults, and Zepbound to treat obstructive sleep apnea in adults with obesity. Researchers are now investigating whether GLP-1s could also treat liver and kidney diseases and curb cravings for alcohol and nicotine.
But here's a twist: while some studies suggest GLP-1s may slow cognitive decline and protect against neurodegenerative diseases, a major setback occurred this week. Two large trials by drugmaker Novo Nordisk found that an oral version of semaglutide, the active ingredient in Ozempic and Wegovy, failed to delay Alzheimer's disease progression in over 3,800 adults with mild cognitive impairment or early dementia.
Dr. Jonathan Rasouli, a neurosurgeon at Northwell's Staten Island University Hospital, commented, "While disappointing, the result was not entirely shocking given the challenging history of Alzheimer's disease drug development. I was hopeful but cautious, as the outcome underscores just how difficult this disease remains to treat."
Despite this setback, the door isn't completely closed on GLP-1s and their potential in treating neurodegenerative diseases. Dr. Maria C. Carrillo, chief science officer at the Alzheimer's Association, stated, "These results will help refine our understanding of this class of drugs. Though this semaglutide pill did not help against Alzheimer's, the field will continue to investigate this class of drugs, as they may act differently."
So, what do you think? Are GLP-1s a promising avenue for treating various conditions, or do the potential side effects outweigh the benefits? We'd love to hear your thoughts in the comments below!
